Gradientech AB (publ) interim report for Q2 2022 is now available on the company’s website www.gradientech.se.
Gradientech AB (publ) interim report for Q2 2022 is now available on the company’s website www.gradientech.se.
Gradientech AB (publ) delårsrapport för Q2 2022 är nu tillgänglig på bolagets hemsida www.gradientech.se.
The diagnostics company Gradientech today announces that instrument and sample preparation kit as part of the previously CE-IVD marked QuickMIC® system, have been registered as IVDR Class A in compliance with the new European IVD regulation.
Diagnostikföretaget Gradientech meddelar idag att instrument och provberedningskit i det sedan tidigare CE-IVD-registrerade QuickMIC®-systemet, har registrerats som IVDR Klass A i enlighet med den nya europeiska IVD-förordningen.
The diagnostics company Gradientech today announces an exclusive distribution agreement with Biomedica for the commercialization of QuickMIC® in Austria, Switzerland and Central Eastern Europe.
Diagnostikföretaget Gradientech har tecknat ett exklusivt distributionsavtal för kommersialiseringen av QuickMIC® i Österrike, Schweiz och östra central Europa med Biomedica.
Gradientech is hosting a live webinar on the 29th of June 2022 at 14:00 (CEST). Current developments in next generation antibiotic susceptibility testing (AST) and state of the art performance with QuickMIC® will be presented.
Gradientech is hosting a live webinar on the 29th of June 2022 at 14:00 (CEST). Current developments in next generation antibiotic susceptibility testing (AST) and state of the art performance with QuickMIC® will be presented.
Gradientech bjuder in till ett direktsänt webinarium den 29 juni 2022 kl. 14:00 (CEST). Aktuell utvecklingen inom nästa generations testning av antibiotikaresistens (AST) och QuickMIC®-systemets prestanda kommer att presenteras.
The diagnostics company Gradientech today announces CE-IVD registration of its first diagnostic product QuickMIC® and its gram-negative panel. The QuickMIC system will be the fastest system for growth-based testing of antibiotic susceptibility for sepsis patients.